Jain K K
Central Drug Monitoring, Medical Department, Ciba-Geigy, Basel, Switzerland.
Drug Saf. 1991 Sep-Oct;6(5):350-60. doi: 10.2165/00002018-199106050-00005.
Records of 80 cases of systemic lupus erythematosus (SLE)-like syndromes associated with use of carbamazepine entered in the single case files of Central Drug Monitoring, Ciba-Geigy, Basel, were reviewed. Included in these were 11 cases reported in the literature. These were assessed in light of the current concepts of both idiopathic and drug-induced forms of SLE. Even allowing for under-reporting of adverse drug reactions, the number of such cases is far below the prevalence rates for SLE. This adverse drug reaction remains allocated to the category 'isolated cases' i.e. frequency is less than 0.001% of the cases treated. Antinuclear antibody (ANA) and anti-double-stranded DNA (anti-dsDNA) tests were not helpful in differentiating between idiopathic and drug-induced SLE. IgG antihistone antibodies in the absence of high titres of dsDNA antibodies is the only reliable test. Symptoms of SLE-like syndromes which manifest after carbamazepine therapy usually subside after discontinuation of the drug. Persistence of symptoms support the diagnosis of idiopathic SLE.
对巴塞尔汽巴 - 嘉基公司中央药物监测单病例档案中记录的80例与使用卡马西平相关的系统性红斑狼疮（SLE）样综合征病例进行了回顾。其中包括文献报道的11例。根据特发性和药物性SLE的当前概念对这些病例进行了评估。即使考虑到药物不良反应报告不足的情况，此类病例的数量仍远低于SLE的患病率。这种药物不良反应仍归为“孤立病例”类别，即发生率低于接受治疗病例的0.001%。抗核抗体（ANA）和抗双链DNA（抗dsDNA）检测无助于区分特发性和药物性SLE。在没有高滴度dsDNA抗体的情况下，IgG抗组蛋白抗体是唯一可靠的检测方法。卡马西平治疗后出现的SLE样综合征症状通常在停药后消退。症状持续则支持特发性SLE的诊断。
